this is the third place/country including the U.S. I remember recently somewhere in Brazil (
link) that had also performed high dose cyclophosphamide on MS patients.
I remember that Lyon had hosted a few articles a while back on his web site that had fairly detailed descriptions of the process used by John Hopkins. If you could get a hold of these and maybe also contact the people in Brazil, I think your medical team will be well informed.
example of some of the details in the document:
Quote:
Approval from the Johns Hopkins institutional review board
was obtained. Patients gave consent twice, at screening and prior
to enrollment into the study if they met all inclusion criteria.
All patient case summaries were presented to a steering committee
to ensure by unanimous approval that they met all inclusion
criteria and no exclusion criteria. Pretreatment studies
included electrocardiogram, echocardiogram or multiple
gated acquisition scan, sinus computed tomography, and extensive
blood work.
Patients received 50 mg/kg/d of Cy intravenously for 4 consecutive
days. The dose of Cy was calculated according to ideal
body weight. Prophylaxis against Cy-induced hemorrhagic
cystitis (generally Mesna [Uromitexan; Baxter, Deerfield, Illinois])
was directed according to established clinical practice
guidelines. On day 6 (6 days after completion of HiCy treatment)
all patients received 5 μg/kg/d of the myeloid growth
factor filgrastim (granulocyte colony–stimulating factor) until
the absolute neutrophil count exceeded 1.0109 cells/L for 2
consecutive days. Patients also routinely received prophylactic
antibiotics (norfloxacin, fluconazole, and valacyclovir) while
granulocytopenic.
I just searched for the docs, and found that you already know of them
link
I would be really interested when someone tries the oral route, which is used for breast cancer. (
link)
Login
Register
FAQ
Search
